Clopidogrel and proton pump inhibitors: A clinically meaningful interaction?

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 2, 2011, Pages 214-218

  Gerhard, Tobias ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PRASUGREL; PROTON PUMP INHIBITOR;

ANTICOAGULANT THERAPY; CORONARY STENT; ENZYME INHIBITION; HUMAN; MEDICAL RECORD; NOTE; OBSERVATIONAL STUDY; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTE AGGREGATION INHIBITION;

DRUG INTERACTIONS; EVIDENCE-BASED MEDICINE; HUMANS; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; RISK ASSESSMENT; TICLOPIDINE;

EID: 78751681251     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2071     Document Type: Note

References (47)

1. IMS Health. Top 15 Global Products, 2009. Http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/Top-Line-Data/Top%2015%20Global%20Products-2009.pdf.
2. Steinhubl SR, Berger PB, Mann JT, III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-2420. DOI:joc21875[pii].
3. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
4. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008. expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008; 118: 1894-1909. DOI:CIRCULATIONAHA.108.191087[pii]10.1161/CIRCULATIONAHA.108.191087.
5. EMEA. Public Statement on Possible Interaction Between Clopidogrel and Proton Pump Inhibitors. Http://www.ema.europa.eu/humandocs/PDFs/EPAR/Plavix/32895609en.pdf [29 March 2009].
6. FDA. Early Communication About an Ongoing Safety Review of Clopidogrel Bisulfate (Marketed as Plavix). Http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/default.htm [21 January 2009].
7. Juurlink DN. Proton pump inhibitors and clopidogrel: putting the interaction in perspective. Circulation 2009; 120: 2310-2312. DOI:CIRCULATIONAHA.109.907295[pii]10.1161/CIRCULATIONAHA.109.907295.
8. Moayyedi P, Sadowski DC. Proton pump inhibitors and clopidogrel - hazardous drug interaction or hazardous interpretation of data? Can J Gastroenterol 2009; 23: 251-252.
9. Sibbing D, Kastrati A. Risk of combining PPIs with thienopyridines: fact or fiction? Lancet 2009; 374: 952-954. DOI:S0140-6736(09)61562-2[pii]10.1016/S0140-6736(09)61562-2.
10. EMEA. Public Statement: Interaction Between Clopidogrel and Proton-Pump Inhibitors Http://www.ema.europa.eu/humandocs/PDFs/EPAR/Plavix/17494810en.pdf [17 November 2009].
11. FDA. Follow-Up to the January 26, Early Communication About an Ongoing Safety Review of Clopidogrel Bisulfate (Marketed as Plavix) and Omeprazole (Marketed as Prilosec and Prilosec OTC). Http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/default.htm [17 November 2009].
12. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-944. DOI:301/9/937[pii]10.1001/jama.2009.261.
13. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180: 713-718. DOI:cmaj.082001[pii]10.1503/cmaj.082001.
14. Rassen JA, Choudhry NK, Avorn J, et al. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009; 120: 2322-2329. DOI:CIRCULATIONAHA.109.873497[pii]10.1161/CIRCULATIONAHA.109.873497.
15. Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med 2010; 152: 337-345. DOI:152/6/337[pii]10.1059/0003-4819-152-6-201003160-00003.
16. Stockl KM, Le L, Zakharyan A, et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med 2010; 170: 704-710. DOI:170/8/704[pii]10.1001/archinternmed.2010.34.
17. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362. DOI:NEJMoa0809171[pii]10.1056/NEJMoa0809171.
18. Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol 2010; 56: 134-143. DOI:S0735-1097(10)01605-0[pii]10.1016/j.jacc.2009.12.071.
19. Kwok CS, Loke YK. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther 2010; 31: 810-823. DOI:APT4247[pii]10.1111/j.1365-2036.2010.04247.x.
20. Laine L, Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am J Gastroenterol 2010; 105: 34-41. DOI:ajg2009638[pii]10.1038/ajg.2009.638.
21. Liu TJ, Jackevicius CA. Drug interaction between clopidogrel and proton pump inhibitors. Pharmacotherapy 2010; 30: 275-289. DOI:10.1592/phco.30.3.27510.1592/phco.30.3.275[pii].
22. Oyetayo OO, Talbert RL. Proton pump inhibitors and clopidogrel: is it a significant drug interaction? Expert Opin Drug Saf. 2010; DOI:10.1517/14740331003645609.
23. Siller-Matula JM, Jilma B, Schror K, et al. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost 2010. [Epub ahead of print]. DOI:10.1111/j.1538-7836.2010.04049.x.
24. Gilard M, Arnaud B, Le Gal G, et al. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 2006; 4: 2508-2509. DOI:JTH2162[pii]10.1111/j.1538-7836.2006.02162.x.
25. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256-260. DOI:S0735-1097(07)03433-X[pii]10.1016/j.jacc.2007.06.064.
26. Li XQ, Andersson TB, Ahlstrom M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004; 32: 821-827. DOI:32/8/821[pii].
27. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009; 101: 714-719. DOI:09040714[pii].
28. Cuisset T, Frere C, Quilici J, et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol 2009; 54: 1149-1153. DOI:S0735-1097(09)02196-2[pii]10.1016/j.jacc.2009.05.050.
29. Clopidogrel. Prescribing Information. Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership. Bridgewater NM.
30. Furuta T, Iwaki T, Umemura K. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br J Clin Pharmacol 2010; 70: 383-392. DOI:BCP3717[pii]10.1111/j.1365-2125.2010.03717.x.
31. Ferreiro JL, Ueno M, Capodanno D, et al. Pharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake: results of a prospective randomized crossover study. Circ Cardiovasc Interv 2010; 3: 436-441. DOI:CIRCINTERVENTIONS.110.957829[pii]10.1161/CIRCINTERVENTIONS.110.957829.
32. Huang CC, Chen YC, Leu HB, et al. Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention. Am J Cardiol 2010; 105: 1705-1709. DOI:S0002-9149(10)00478-9[pii]10.1016/j.amjcard.2010.01.348.
33. Kreutz RP, Stanek EJ, Aubert R, et al. Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel medco outcomes study. Pharmacotherapy 2010; 30: 787-796. DOI:10.1592/phco.30.8.78710.1592/phco.30.8.787[pii].
34. Tsai YW, Wen YW, Huang WF, et al. Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding. J Gastroenterol 2010. [Epub ahead of print]. DOI:10.1007/s00535-010-0299-0.
35. van Boxel OS, van Oijen MG, Hagenaars MP, et al. Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study. Am J Gastroenterol 2010; 105: 2430-2436. DOI:ajg2010334[pii]10.1038/ajg.2010.334.
36. Stanek EJ, Aubert RE, Flockhart DA, et al. A national study of the effect of individual proton pump inhibitors on cardiovascular outcomes in patients treated with clopidogrel following coronary stenting: the Clopidogrel in Medco Outcomes Study. Presented at 32nd Annual Scientific Sessions. Society of Cardiovascular Angiography and Intervention, May 6, 2009.
37. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374: 989-997. DOI:S0140-6736(09)61525-7[pii]10.1016/S0140-6736(09)61525-7.
38. Dunn SP, Macaulay TE, Brennan DM, et al. Abstract 3999: baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Circulation 2008; 118: S-815-a.
39. Bhatt DL, Cryer B, Contant CF, et al. The COGENT Trial; Transcatheter Cardiovascular Therapeutics; September 24, 2009, San Francisco, California (Abstract).
40. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45, 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607-1621. DOI:S0140-6736(05)67660-X[pii]10.1016/S0140-6736(05)67660-X.
41. Granger CB. ACP Journal Club. Concomitant use of proton pump inhibitors with clopidogrel may increase risk for readmission after discharge for acute MI. Ann Intern Med 2009; 151: JC2-13. DOI:151/4/JC2-j-13[pii].
42. Schneider-Lindner V, Filion KB, Brophy JM. Adverse outcomes associated with use of proton pump inhibitors and clopidogrel. JAMA 2009; 302: 29-30 (Author Reply 1). DOI:302/1/29-a[pii]10.1001/jama.2009.897.
43. Alegre-del Rey EJ, Sierra-Sanchez J, Castano-Lara R, et al. Peptic disease: a confounding factor for proton pump inhibitor-clopidogrel interaction? Am J Cardiol 2010; 106: 294-295 (Author Reply 5). DOI:S0002-9149(10)00944-6[pii]10.1016/j.amjcard.2010.04.008.
44. Aleil B, Leon C, Cazenave JP, et al. CYP2C19*2 polymorphism is not the sole determinant of the response to clopidogrel: implications for its monitoring. J Thromb Haemost 2009; 7: 1747-1749. DOI:JTH3554[pii]10.1111/j.1538-7836.2009.03554.x.
45. Ferreiro JL, Angiolillo DJ. Clopidogrel response variability: current status and future directions. Thromb Haemost 2009; 102: 7-14. DOI:TH09-03-0185[pii]10.1160/TH09-03-0185.
46. Hochholzer W, Trenk D, Fromm MF, et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 2010; 55: 2427-2434. DOI:S0735-1097(10)01151-4[pii]10.1016/j.jacc.2010.02.031.
47. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53: 849-856. DOI:S0735-1097(08)03972-7[pii]10.1016/j.jacc.2008.11.030.